Shopping Cart 0
Cart Subtotal
USD 0

Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H2, 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500

Details

Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H2, 2018

Summary

GlobalData's clinical trial report, Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H2, 2018" provides an overview of Transitional Cell Cancer (Urothelial Cell Cancer) clinical trials scenario. This report provides top line data relating to the clinical trials on Transitional Cell Cancer (Urothelial Cell Cancer). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

GlobalData Clinical Trials Report Coverage 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14

Top Five Countries Contributing to Clinical Trials in Central and South America 15

Clinical Trials by G7 Countries: Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials 16

Clinical Trials by Phase in G7 Countries 18

Clinical Trials in G7 Countries by Trial Status 19

Clinical Trials by E7 Countries: Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials 21

Clinical Trials by Phase in E7 Countries 23

Clinical Trials in E7 Countries by Trial Status 24

Clinical Trials by Phase 26

In Progress Trials by Phase 27

Clinical Trials by Trial Status 28

Clinical Trials by End Point Status 30

Subjects Recruited Over a Period of Time 31

Clinical Trials by Sponsor Type 32

Prominent Sponsors 33

Top Companies Participating in Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials 35

Prominent Drugs 37

Latest Clinical Trials News on Transitional Cell Cancer (Urothelial Cell Cancer) 39

Jul 09, 2018: Seattle Genetics completes enrolment in EV-201 trial 39

Clinical Trial Profile Snapshots 40

Appendix 618

Abbreviations 618

Definitions 618

Research Methodology 619

Secondary Research 619

About GlobalData 619

Contact Us 620

Disclaimer 620

Source 620


List Of Figure

List of Figures

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Region (%), 2018* 7

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15

Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, G7 Countries (%), 2018* 16

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19

Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, E7 Countries (%), 2018* 21

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 24

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 26

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 27

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 28

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 32

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 33

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 35

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 37

GlobalData Methodology 619


List Of Table

List of Tables

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Region, 2018* 7

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15

Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, G7 Countries (%), 2018* 17

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20

Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, E7 Countries (%), 2018* 22

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Phase, 2018* 26

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 27

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 29

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 32

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 34

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 36

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 38

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Transitional Cell Cancer (Urothelial Cell Cancer) Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Transitional Cell Cancer (Urothelial Cell Cancer), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania


Companies

F. Hoffmann-La Roche Ltd

Merck & Co Inc

Bristol-Myers Squibb Co

AstraZeneca Plc

Pfizer Inc

Eli Lilly and Co

Incyte Corp

GlaxoSmithKline Plc

Bayer AG

Amgen Inc

Company Profile

Company Profile Title

Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H2, 2018

Summary

GlobalData's clinical trial report, Transitional Cell Cancer (Urothelial Cell Cancer) Global Clinical Trials Review, H2, 2018" provides an overview of Transitional Cell Cancer (Urothelial Cell Cancer) clinical trials scenario. This report provides top line data relating to the clinical trials on Transitional Cell Cancer (Urothelial Cell Cancer). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Report Guidance 5

GlobalData Clinical Trials Report Coverage 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14

Top Five Countries Contributing to Clinical Trials in Central and South America 15

Clinical Trials by G7 Countries: Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials 16

Clinical Trials by Phase in G7 Countries 18

Clinical Trials in G7 Countries by Trial Status 19

Clinical Trials by E7 Countries: Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials 21

Clinical Trials by Phase in E7 Countries 23

Clinical Trials in E7 Countries by Trial Status 24

Clinical Trials by Phase 26

In Progress Trials by Phase 27

Clinical Trials by Trial Status 28

Clinical Trials by End Point Status 30

Subjects Recruited Over a Period of Time 31

Clinical Trials by Sponsor Type 32

Prominent Sponsors 33

Top Companies Participating in Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials 35

Prominent Drugs 37

Latest Clinical Trials News on Transitional Cell Cancer (Urothelial Cell Cancer) 39

Jul 09, 2018: Seattle Genetics completes enrolment in EV-201 trial 39

Clinical Trial Profile Snapshots 40

Appendix 618

Abbreviations 618

Definitions 618

Research Methodology 619

Secondary Research 619

About GlobalData 619

Contact Us 620

Disclaimer 620

Source 620


List Of Figure

List of Figures

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Region (%), 2018* 7

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15

Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, G7 Countries (%), 2018* 16

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19

Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, E7 Countries (%), 2018* 21

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 24

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 26

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 27

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 28

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 32

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 33

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 35

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 37

GlobalData Methodology 619


List Of Table

List of Tables

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Region, 2018* 7

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15

Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, G7 Countries (%), 2018* 17

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20

Proportion of Transitional Cell Cancer (Urothelial Cell Cancer) to Oncology Clinical Trials, E7 Countries (%), 2018* 22

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Phase, 2018* 26

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 27

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 29

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 30

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 31

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 32

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 34

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 36

Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Transitional Cell Cancer (Urothelial Cell Cancer) Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Transitional Cell Cancer (Urothelial Cell Cancer), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania


Companies

F. Hoffmann-La Roche Ltd

Merck & Co Inc

Bristol-Myers Squibb Co

AstraZeneca Plc

Pfizer Inc

Eli Lilly and Co

Incyte Corp

GlaxoSmithKline Plc

Bayer AG

Amgen Inc